Segmental Reporting (Tables)

9 Months Ended

Sep. 30, 2014

Segment Reporting [Abstract]

Schedule of Segment Revenue from Major Products

9 months to,	September 30,	September 30,
	2014	2013
	$’M	$’M
	___________	___________
VYVANSE	1,065.6	897.9
LIALDA/MEZAVANT	449.1	379.9
ELAPRASE	449.5	392.6
CINRYZE	360.6	-
REPLAGAL	380.7	336.6
FIRAZYR	262.3	153.8
INTUNIV	279.0	248.9
VPRIV	273.0	251.9
ADDERALL XR	280.2	293.5
PENTASA	213.8	215.2
FOSRENOL	136.2	136.3
XAGRID	82.1	74.1
Other product sales	97.6	96.4
	____________	____________
Total product sales	4,329.7	3,477.1
	____________	____________